Biomarkers of clinical benefit associate with erlotinib treatment in NSCLC

An analysis of biomarkers in patients treated with erlotinib and platinum therapy in non small cell lung cancer (NSCLC) shows that (measured by fluorescence in situ hybridization, FISH) positive status correlated with improved outcome

AstraZeneca’s VEGF inhibitor cediranib inhibits VEGFR3 activity as well as VEGFR1 and VGFR2

Data published in Cancer Research show that AstraZeneca’s VEGF inhibitor Cediranib inhibits VEGFR-3 activity as well as VEGFR1 and VEGFR2

Mercury report on AMPK program – lead compounds found to be orally bioavailable

Mercury Therapeutics has announced progress in its AMPK program for Type-2 diabetes. Compounds from two lead series have been found to be orally bioavailable.

SuperGens JAK2 inhibitor SGI-1252 inhibits tumor cell proliferation in vivo

Data presented at the European Hematology Association show SuperGen’s JAK2 inhibitor SGI-1252 to inhibitor tumor cell proliferation in mouse xenograft models.

Exelixis prepare for Phase III trial of its Met/Ret/VEGFR2 inhibitor XL184 in medullary thyroid cancer

Exelixis and the US FDA have reached an agreement on Phase III trial design for its Met/Ret/VEGFR2 inhibitor XL184 in medullary thyroid cancer. The trial is expected to start this summer